Contribute Try STAT+ Today

biologics

Most Read

Human T cells showing nuclei

Business By Sharon Begley

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

Medication

First Opinion By Jonathan Kimball

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pills

First Opinion By Carlos Sattler and Sheila Frame

Biosimilar approval and adoption in the U.S. needs to be expedited

Hello my name is...

First Opinion By Brad Jordan

U.S. biologics and biosimilars need distinguishable names

Herceptin

First Opinion By Michelle Hoffmann

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

Pharmalot By Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Pharmalot By Ed Silverman

Bill introduced to speed cheaper versions of pricey biologics to market

A magnified view of C. difficile bacteria.

Biotech By Kate Sheridan

Microbiome-based drugs likely to face FDA’s biologics pathway

All Coverage

First Opinion By Sean McGowan

Five years on, biosimilars need support from all health care players

Infusion drip

First Opinion By Leah Christl

From bench to bedside, biologics require excellence at every stage

advertisement

USMCA

First Opinion By John E. Osborn

Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward

Vial and syringe

Politics By Nicholas Florko

Lawmakers slip a win for pharma into federal spending package

The Capitol Dome - fog

Politics By Erin Mershon

Drug makers jostle over potential Medicare changes in congressional spending deal

South Korea Samsung Biologics

Business By Associated Press

Samsung’s biotech unit debuts in Seoul. Here’s what to know

Biomolecular manufacturing kit

In the Lab By Eric Boodman

Freeze-dried drug factories could make a slew of medicines — just add water

Pharmalot By Ed Silverman

Biosimilar names may affect pharmacist dispensing habits

Pharmalot By Ed Silverman

Some biosimilars are just as good as some pricey biologics

Pharmalot By Ed Silverman

Court ruling on biosimilar launches could increase health care costs

Supreme Court

Pharmalot By Ed Silverman

Supreme Court asks Obama administration for views on biosimilar rules

Pharmalot By Ed Silverman

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

FDA Campus

Pharmalot By Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers